Elsan
Marseille
What changed
Study registered, no phase assigned: Comparison of Two Early Treatments for Premature Babies and Their Effects Over Time
7mo agoTrial registeredDec 3, 2025Source filing (opens the source filing in a new tab)
Momentum
Momentum 46 out of 100, unchanged since the last recompute.
Some recent activity, at a steady rate.
Runway (estimate)
No disclosed raise on file, so there is nothing to model from.
Stage
Grant-only
The furthest-along thing in the public record. Not a projection.
Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.
Grant to raise
Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.
- Trial
NA registered
Dec 1, 2025Premature - Weight 1000g-2499g or Gestation of 28-37weeks, Premature Baby 26 to 32 Weeks, Premature Baby 33 to 36 Weeks, Premature Between 32 and 36 Weeks of Amenorrhoea · NOT_YET_RECRUITING · sponsor: Elsan · Comparison of Two Early Treatments for Premature Babies and Their Effects Over Time
ClinicalTrials.gov · NCT07261046 (opens the source filing in a new tab)
Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources